GANX | Gain Therapeutics, Inc.

Index	-	P/E	-	EPS (ttm)	-1.64	Insider Own	24.34%	Shs Outstand	11.94M	Perf Week	6.94%
Market Cap	59.31M	Forward P/E	-	EPS next Y	-1.49	Insider Trans	0.00%	Shs Float	8.99M	Perf Month	-4.46%
Income	-19.50M	PEG	-	EPS next Q	-0.28	Inst Own	10.20%	Short Float / Ratio	0.61% / 0.65	Perf Quarter	25.13%
Sales	0.20M	P/S	296.54	EPS this Y	-8.30%	Inst Trans	12.98%	Short Interest	0.06M	Perf Half Y	62.17%
Book/sh	1.27	P/B	3.88	EPS next Y	0.00%	ROA	-73.70%	Target Price	9.00	Perf Year	72.98%
Cash/sh	1.48	P/C	3.33	EPS next 5Y	-	ROE	-93.00%	52W Range	2.67 - 6.19	Perf YTD	57.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-91.60%	52W High	-20.36%	Beta	-
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-	Gross Margin	-	52W Low	84.64%	ATR	0.30
Employees	28	Current Ratio	3.70	Sales Q/Q	47.00%	Oper. Margin	-	RSI (14)	51.82	Volatility	5.16% 6.39%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-56.30%	Profit Margin	-	Rel Volume	0.56	Prev Close	4.81
Shortable	Yes	LT Debt/Eq	0.03	Earnings	Mar 23 AMC	Payout	-	Avg Volume	84.89K	Price	4.93
Recom	1.50	SMA20	-0.64%	SMA50	0.27%	SMA200	27.08%	Volume	47,680	Change	2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-21	Initiated	Oppenheimer	Outperform	$30
Apr-12-21	Initiated	BTIG Research	Buy	$30

Jun-01-23 08:00AM	Gain Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-23 08:09AM	Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 09:15AM	Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-08-23 10:00AM	Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:15AM	Loading…
May-03-23 09:15AM	Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinsons Disease (GlobeNewswire)
Apr-12-23 04:30PM	Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer (GlobeNewswire)
Mar-29-23 08:52AM	Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting (GlobeNewswire)
Mar-23-23 04:05PM	Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Mar-22-23 08:30AM	Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders (GlobeNewswire)
Mar-21-23 08:00AM	Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program (GlobeNewswire) +5.31%
Mar-09-23 08:00AM	Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) -5.08%
Feb-27-23 08:00AM	Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium (GlobeNewswire)
Feb-02-23 08:00AM	Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
04:05PM	Loading…
Jan-12-23 04:05PM	Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference (GlobeNewswire)
Nov-10-22 05:15PM	Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:02PM	Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Sep-26-22 11:59AM	Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program (Benzinga)
08:00AM	Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinsons Disease Patient-Derived Dopaminergic Neurons (GlobeNewswire)
Sep-20-22 07:30AM	Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer (GlobeNewswire)
Sep-19-22 08:00AM	Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinsons Disease (GlobeNewswire) -7.39%
Sep-08-22 08:00AM	Gain Therapeutics to Present Data at Upcoming Medical Meetings (GlobeNewswire)
Sep-06-22 08:00AM	Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-08-22 09:15AM	Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Aug-04-22 08:00AM	Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference (GlobeNewswire)
Aug-03-22 10:00AM	Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jun-02-22 08:00AM	Gain Therapeutics to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 08:00AM	Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
05:55PM	Loading…
May-16-22 05:55PM	Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
May-11-22 09:30AM	Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium (GlobeNewswire) -13.17%
May-06-22 08:00AM	Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinsons Disease at XXVII IAPRD World Congress (GlobeNewswire) -11.37%
May-03-22 08:31AM	Cloopen Announced Formation of Independent Special Committee for Internal Investigation (PR Newswire) +11.80%
May-02-22 03:00PM	Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-22 05:19PM	Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference (GlobeNewswire) -8.12%
Apr-12-22 01:00PM	Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinsons Disease at the 2022 Synuclein Meeting (GlobeNewswire) -7.40%
Mar-29-22 08:00AM	Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference (GlobeNewswire)
Mar-24-22 08:00AM	Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update (GlobeNewswire)
Mar-15-22 08:00AM	Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinsons and Alzheimers Disease at the AD/PD 2022 Conference (GlobeNewswire)
Mar-01-22 08:00AM	Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences (GlobeNewswire) +5.15%
Feb-08-22 08:00AM	Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022 (GlobeNewswire) -6.81%
Feb-04-22 12:06PM	Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day (GlobeNewswire)
Jan-31-22 04:05PM	Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day (GlobeNewswire)
Jan-18-22 08:00AM	Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences (GlobeNewswire)
Jan-06-22 04:05PM	Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference (GlobeNewswire)
Dec-28-21 04:05PM	Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.43%
Dec-16-21 06:57AM	What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own? (Simply Wall St.)
Dec-07-21 08:00AM	Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update (GlobeNewswire) +8.80%
Dec-01-21 04:07PM	Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit (GlobeNewswire)
Nov-12-21 09:52AM	2 Strong Buy Stocks Under $10 With Triple-Digit Upside (TipRanks) +10.29%
07:00AM	Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Nov-11-21 11:00AM	Gain Therapeutics Presents Parkinsons Disease Preclinical Study Results at Society for Neuroscience Annual Meeting (GlobeNewswire)
Nov-10-21 11:00AM	Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinsons Disease and Gaucher Disease (GlobeNewswire) +9.48%
Nov-04-21 04:05PM	Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Oct-28-21 08:00AM	Gain Therapeutics to Present at Upcoming Medical Conferences (GlobeNewswire)
Oct-26-21 08:00AM	Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB) (GlobeNewswire)
Oct-19-21 08:00AM	Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer (GlobeNewswire)
Oct-12-21 10:07AM	Gain Therapeutics' SEE-Tx Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding (Benzinga)
Sep-23-21 08:00AM	Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-17-21 08:00AM	Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) +7.01%
Sep-09-21 04:20PM	Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference (GlobeNewswire)
Sep-08-21 03:51PM	Why Gain Therapeutics Shares Are Trading Higher Today (Benzinga) +20.13%
11:42AM	Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study (Benzinga)
09:08AM	Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinsons Disease (GlobeNewswire)
07:29AM	Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinsons Disease (GlobeNewswire)
Sep-02-21 04:05PM	Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-11-21 04:01PM	Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Aug-03-21 04:05PM	Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-21-21 05:49PM	Is Gain Therapeutics, Inc. (GANX) A Good Stock To Buy? (Insider Monkey)
Jun-19-21 05:49AM	What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own? (Simply Wall St.)
Jun-10-21 07:30AM	Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders (GlobeNewswire)
May-27-21 08:00AM	Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-17-21 08:00AM	Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May (GlobeNewswire)
May-10-21 04:01PM	Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results (GlobeNewswire)
May-03-21 07:30AM	Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinsons Disease & Related -synucleopathies at the XXVI IAPRD World Congress (GlobeNewswire)
Apr-27-21 04:01PM	Gain Therapeutics to Present at the B. Riley Securities Virtual Neuroscience Conference (GlobeNewswire)
Apr-22-21 08:00AM	Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress (GlobeNewswire)
Apr-20-21 08:00AM	Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals (GlobeNewswire)
Apr-14-21 09:13PM	Investing in These 2 Stocks Could Double Your Money, Say Analysts (TipRanks) +6.24%
07:00AM	Coya Therapeutics Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors (GlobeNewswire)
Mar-25-21 05:57PM	Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Overallotment Option to Purchase Additional Shares (GlobeNewswire)
Mar-18-21 05:08PM	These 4 IPOs Made Their Market Debuts Thursday. Heres How They Did. (Barrons.com)
08:16AM	The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq (Benzinga)
07:00AM	Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock (GlobeNewswire)

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GANX | Gain Therapeutics, Inc.

Upgrade your FINVIZ experience